Genen­tech yanks Gavre­to's rare thy­roid can­cer in­di­ca­tion, months be­fore hand­ing it back to Blue­print

Roche sub­sidiary Genen­tech is yank­ing Gavre­to’s ac­cel­er­at­ed ap­proval for a type of thy­roid can­cer af­ter de­ter­min­ing a con­fir­ma­to­ry study is no longer fea­si­ble.

The ki­nase …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.